By Dennis Thompson HealthDay ReporterWEDNESDAY, Dec. 17, 2025 (HealthDay News) — An over-the-counter supplement called lipoic ...

Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...

French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis ...

A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...

Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t ...

If gut bacteria are too similar to the protective layer of nerves, they can misdirect the immune system and cause it to ...

Disease-modifying therapies for MS that prevent brain volume loss are linked to reduced long-term disability, new data show.

The over-the-counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the ...

People typically develop multiple sclerosis between ages 20 and 40, but late-onset MS affects those 50 years and older. Your doctor can best diagnose and advise on possible treatments, such as ...

People who have been exposed to both PFAS and PCBs are more likely to be diagnosed with multiple sclerosis (MS). These new ...

Heat sensitivity in multiple sclerosis is well known, but doctors say cold weather can also worsen symptoms. From nerve ...